Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 24, 2012

View Archived Issues

Interim results reported from phase I/IIa ensituximab trial

PG-545 is active in several models of pancreatic cancer

GlaxoSmithKline scientists describe synthesis and preclinical testing of epelsiban

Biomarker of biliary tract carcinomas identified

Boehringer Ingelheim discloses novel 11-beta-HSD1 inhibitors

New free fatty acid FFA1 receptor agonists patented by Sanofi

Sanofi presents new casein kinase I inhibitors

La Jolla Pharmaceutical acquires rights to first-in-class galectin-3 inhibitor

Scientists at Roche prepare new GlyT-1 inhibitors

Sosei and Ceolia Pharma sign technical alliance agreement

Seikagaku launches phase II SI-614 study

FDA authorizes marketing of Quest Diagnostics test and label change for Tysabri

Chemotherapy combined with radiation shows promise in oligodendroglioma subtype

New serine/threonine-protein kinase B-raf inhibitors synthesized by Novartis

Italian company patents new muscarinic acetylcholine M3 receptor antagonists

ImmunoCellular Therapeutics provides update on phase III ICT-107 study

Treatment begins in Europe's first clinical study of hESC-derived cell therapy

Leeds University study reveals potential biomarker to monitor GIST progression

FDA extends PDUFA date for Adasuve NDA

Trius Therapeutics earns milestone payment from tedizolid collaboration

CHMP recommends updating Glivec label in Europe

Santhera regains fipamezole rights

BioAlliance Pharma advances its AMEP biotherapy

FDA approves subcutaneous Velcade

Medicure gives update on drug candidate for tardive dyskinesia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...